Trial · NCT04099901
Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial
NCT04099901, Phase 2, Completed, Radboud University Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial. Trials, record NCT04099901. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04099901
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial
- NCT number
- NCT04099901
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 88 participants, actual
- Lead sponsor
- Radboud University Medical Center
- Conditions
- Multiple Myeloma
- Interventions
- Anakinra, Placebos
- First posted
- 2019-09-23
- Last updated
- 2024-11-18
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction of the incidence of fever during neutropenia | Primary outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Reduction in incidence of mucositis-related fever | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Daily mean CRP level | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Intestinal mucositis as measured by the area-under-the-curve of reciprocal citrulline levels | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Clinical mucositis as determined by the daily mouth and gut scores | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Days with fever (≥ 38.5° C) | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Incidence of bloodstream infections i.e. bacteremia | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Length of hospital stay in days | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Use of systemic antimicrobial agents (incidence and duration) | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). | |
| Secondary | Use of analgesic drugs (incidence and duration) | Outcome will be determined during the period of hospitalization (day of admission [day -3] until discharge, maximum period +30 days). |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33225965 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04099901
GET https://conductscience.org/api/trials/v1/NCT04099901/registered